OOIR: Observatory of International Research

Papers

(The H4-Index of Value in Health is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Author Reply	719
Editorial Board	599
When Do Value-Based Contracts Add Value? Insights From Probabilistic Simulations	128
A Head-to-Head Comparison of the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D in Children With Asthma	110
POSC161 Cost-Consequence Analysis of Rosuvastatin Versus Atorvastatin in the Spanish Setting	101
POSA371 Barriers and Expectations for Patients in Post-Osteoporotic Fractures Care in France: The Effel Study	97
POSA373 Evaluation of Ehealth Literacy Measurement Tools and Its Associated Factors: A Systematic Review and Meta-Analysis	77
POSB42 The Health-Economic Evaluation of Risdiplam in Patients with Spinal Muscular Atrophy	75
POSB62 Budget Impact Analysis of Ertugliflozin Inclusion in the List of Vital and Essential Medicines in Russian Federation	67
POSB55 Economic Consequences of Anti-HCV Treatment of Patients Diagnosed through Screening in Italy: A Prospective Modelling Analysis	67
A Systematic Review of International Guidance for Self-Report and Proxy Completion of Child-Specific Utility Instruments	64
HSD101 Lack of concordance between real-world treatment patterns and clinical guideline recommendations for metastatic hormone-sensitive prostate cancer (mhspc) patients	63
Table of Contents	63
EE237 The Risk-Based Price: Incorporating Uncertainty and Risk Attitues in Health Technology Pricing	63
RWD48 Inpatient Resource Utilization Outcomes Among Patients Living with Fragile X Syndrome and Comorbid Autism Spectrum Disorder in the US	60
P32 Power Implications of Estimator Choice in Synthetic Control Arm Analyses: Results from a Simulation Comparing Average Treatment Effects on the Treated and Untreated Under Propensity Score Weightin	59
HSD129 Managing Members with Complex Conditions: A Blue Cross and Blue Shield of Louisiana Program Evaluation	58
Editorial Board	58
RWD86 Healthcare Resource Utilization and Economic Burden of Patients with Gout in the United States	54
HTA35 Testing and Piloting of a Value Framework for Diagnostic Technologies in Latin America	53
EE467 Recovid Study. Cost-Effectivness Analysis of Using Nutridrink 200 ML in the Treatment of COVID-19 in the Hospital	52
RWD116 Reduced Lysosomal Acid Lipase Activity in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Current Evidence and Future Directions	51
RWD120 Impact of Healthcare Fragmentation on Survival of Patients with Colorectal Cancer in Colombia	46
EE498 Economic Burden of Interstitial Lung Disease in a Commercially Insured Population with Sjogren's Syndrome in the United States	45
HTA49 Determining Appropriate Health Economic Modeling Approaches in Fabry Disease	45

RWD118 Rapid Diversification of Immune Checkpoint Inhibitor Usage in Community Health Systems in the US Following New Drug Approvals	42
EPH139 COVID-19 Vaccine Related Adverse Events in a Population Aged 5–17 Years: A Study of Reports from the VAERS Database	42
HTA48 Minimum Follow-up Time Required for the Detection of the Impact of Treatments on Neuropathic Pain and Gastrointestinal Complaints in Fabry Disease	41
RWD140 Using Machine Learning to Identify Non-Metastatic Castration-Resistant Prostate Cancer (NMCRPC) Patients from Electronic Health Record Data	40
HTA70 Forecasting Drug Price for Reimbursement By Utilizing a Value-Price Relationship, a Case Study in Hormone-Relapsed Prostate Cancer	40
RWD142 Clinical Characteristics of Chinese Patients with Psoriasis Receiving Interleukin-17A Inhibitors: A Single-Center Retrospective Analysis	39
EPH23 Sociodemographic and Clinical Characteristics of Patients with Atopic Dermatitis in Colombia:Preliminary Results of Rendac	37
PCR71 Health State Utilities in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib or Sunitinib	34
SA11 Data Visualization: A Tool to Enhance the Interpretability of Complex and Dense Data Sources	34